Loading clinical trials...
Loading clinical trials...
A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Conditions
Interventions
Rituximab-Dexamethasone-Lenalidomide
Locations
18
Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia
Meldola, Forlì-Cesena, Italy
A.O. C. Panico - U.O.C Ematologia e Trapianto
Tricase, Lecce, Italy
Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS - Ematologia
Reggio Emilia, Reggio Emilia, Italy
Ospedale Dell'Angelo - U.O. Ematologia
Mestre, Venezia, Italy
Clinica di Ematologia A.O.Universitaria Ospedali Riuniti, Ancona
Ancona, Italy
A.O. Spedali Civili di Brescia - Ematologia
Brescia, Italy
Start Date
September 1, 2016
Primary Completion Date
September 22, 2020
Completion Date
November 24, 2022
Last Updated
December 23, 2022
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions